Phio Pharmaceuticals submits FDA filing for PH-762 to advance into next stage of clinical development in cutaneous squamous cell carcinoma. FDA submission advances PH-762 into next clinical stage for cutaneous squamous cell carcinoma.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | 2 | 2 | — | — | — | — | — | 1 | — | 2 | 1 |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2018 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 8.49 | 5.38 | 21.03 | 13.00 |
| Receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 9.32 | 5.74 | 21.48 | 14.30 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 0.66 | 0.25 | 0.44 | 0.90 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 1.63 | 1.02 | 1.34 | 1.71 |
| 10y | 5y | 3y | |
| Sales | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’19 | 0.02 | — | — | — |
0.02
|
| ’18 | 0.02 | 0.06 | 0.06 | 0.00 |
0.14
|
| ’17 | — | — | — | — |
0.02
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (4.00) | (4.03) | — | — |
—
|
| ’25 | (1.27) | (2.54) | (2.08) | (2.08) |
(7.98)
|
| ’24 | (2.01) | (1.78) | (1.95) | (1.37) |
(7.11)
|
| ’23 | (2.71) | (2.77) | (2.90) | (2.37) |
(10.75)
|
| ’22 | (3.47) | (2.43) | (3.53) | (2.70) |
(12.13)
|
| ’21 | (3.27) | (3.25) | (2.87) | (2.47) |
(11.86)
|
| ’20 | (2.18) | (2.03) | (1.97) | (2.62) |
(8.80)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (4.00) | (4.03) | — | — |
—
|
| ’25 | (1.28) | (2.54) | (2.09) | (2.08) |
(7.99)
|
| ’24 | (2.01) | (1.78) | (1.95) | (1.36) |
(7.10)
|
| ’23 | (2.71) | (2.78) | (2.90) | (2.37) |
(10.75)
|
| ’22 | (3.57) | (2.44) | (3.53) | (2.70) |
(12.25)
|
| ’21 | (3.27) | (3.27) | (2.90) | (2.47) |
(11.91)
|
| ’20 | (2.19) | (2.03) | (1.98) | (2.62) |
(8.82)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.34) | (0.36) | — | — |
—
|
| ’25 | (0.41) | (0.45) | (0.44) | (0.15) |
(1.45)
|
| ’24 | (4.23) | (3.62) | (1.54) | (0.85) |
(9.08)
|
| ’23 | (28.35) | (13.23) | (10.26) | (1.53) |
(46.80)
|
| ’22 | (20.53) | (20.53) | (28.09) | (2.40) |
(90.91)
|
| ’21 | (34.58) | (21.61) | (30.25) | (27.01) |
(112.38)
|
| ’20 | (143.71) | (36.74) | (43.22) | (44.30) |
(207.46)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 35.10 | 6.30 | 1.53 | 0.97 | — | — | — |
Low Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 261.36 | 110.43 | 10.35 | 9.79 | — | — | — |
High Price
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 10 | 9 | 5 | 6 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | — | — | — | — | — |
Revenue
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | — | — | — | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (11.48) | (10.83) | (7.15) | (8.70) | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | ‡‡‡ | ‡‡‡ | — |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (11.48) | (10.83) | (7.15) | (8.70) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.07 | 0.06 | 0.00 | 0.00 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | — |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (90.91) | (46.80) | (9.08) | (1.45) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (96.03) | (46.33) | (9.04) | (1.33) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.96) | (0.02) | 0.01 | 0.00 | ‡‡‡ | ‡‡‡ | — |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (96.99) | (46.35) | (9.03) | (1.34) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 85.81 | 33.32 | 6.00 | 3.37 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.13 | 0.23 | 0.79 | 5.98 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Shares
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | — |
PS Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | — |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | — | — | — | — | — |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | — | — | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.13) | (10.75) | (7.11) | (7.98) | ‡‡‡ | ‡‡‡ | — |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.12) | 0.00 | 0.01 | (0.01) | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.25) | (10.75) | (7.10) | (7.99) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 10.51 | 7.69 | 4.72 | 20.14 | — | — | — |
Working Cap'
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.17 | — | — | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (11.66) | (8.49) | (5.38) | (21.03) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 10.84 | 7.73 | 4.72 | 20.15 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (60.45%) | (97.63%) | (94.69%) | (63.90%) | — | — | — |
ROA
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (70.06%) | (116.61%) | (114.83%) | (69.95%) | — | — | — |
ROE
|
Phio Pharmaceuticals Corp. (PHIO), a microcap biotech pinned on its INTASYL RNAi platform for immuno-oncology, exemplifies desperate innovation amid financial ruin. With just 5 employees in 2024, the company has scorched through cash for a decade, diluting shareholders over 7,870 times since 2016—shares surging from 100,000 to a projected 10.76 million by 2025—while book value per share plummeted 99.6% to $6. Revenue vanished post-2019 (zero since), net losses persist at $7-13 million annually, ROE wallows at -115%, and cumulative free cash flow bleed tops $80 million, all propped by relentless equity raises.
Insiders signal faint optimism, with the CEO, Chairman, and others buying ~$49,000 in shares across 2025 purchases and zero sells, amid analyst consensus targeting 750% upside from early 2026 levels. Yet contrarian flags abound: 2025 forecasts eye a miraculous $75 million revenue leap (100x prior) and positive EBT, clashing with trial setbacks, leadership churn, workforce cuts, and RNAi giants like Alnylam looming.
This high-risk lottery tempts with explosive potential if commercialization hits, but history screams caution—90% of similar biotechs delist or dilute to dust. Approach only with house money, as dilution death spirals and Phase 2 failure rates over 70% threaten sub-$1 oblivion.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.